Identifying and addressing barriers to the delivery of optimal therapy for primary central nervous system lymphoma in the broader community.
Despite recent advances in the management of primary central nervous system lymphoma (PCNSL), recent population-based studies suggest that prognosis in the broader community has not improved substantially over the last 20 years. It is possible that this difference in outcome reflects a significant selection bias in the clinical series and trials reported. However, there is also preliminary evidence suggesting that patients in the community may not receive optimal management. There are many possible reasons that might account for disparities in care and outcome, but these have not been specifically addressed with regard to PCNSL. We have sought to elaborate some potential causes of these disparities; however, future studies are needed to identify and address specific barriers to care in the community.
Abrey
Lauren E
LE
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA. abreyl@mskcc.org
Panageas
Katherine S
KS
D000368:Aged; D001932:Brain Neoplasms / Q000628:therapy; D016543:Central Nervous System Neoplasms / Q000628:therapy*; D002986:Clinical Trials as Topic; D003153:Community Health Services / Q000458:organization & administration*; D006297:Health Services Accessibility; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008495:Medical Oncology / Q000458:organization & administration*; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D016896:Treatment Outcome